PhaseBio Pharma and BioVectra to Support Development and Commercialization of Monoclonal Antibody

"PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab"

PhaseBio’s lead product candidate currently in a global Phase 3 clinical trial. Bentracimab is a novel, human monoclonal antibody fragment that in earlier clinical trials has shown immediate and sustained reversal of the antiplatelet effects of Brilinta® (ticagrelor)...

031221 PhaseBio Pharmaceuticals and BioV

.

Download • 549KB